Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS Opdivo To Make Splash in Blood Cancer

Executive Summary

New data show that Bristol-Myers Squibb Co.'s Opdivo (nivolumab) has promise in treating Hodgkin's lymphoma reinforcing the notion that checkpoint inhibitors have potential in a broad range of cancers.

You may also be interested in...



Seattle Genetics/BMS Blood Cancer Tie-Up May Expand After Good Combo Data

Combo of Seattle Genetics' antibody-drug conjugate Adcetris and BMS's PD-1 inhibitor Opdivo demonstrates 90% objective response rate and 62% complete response rate in relapsed Hodgkin lymphoma, and further investigation of the pairing seems on the cards.

Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda

Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.

Merck's Keytruda Gets Lung Cancer Nod In Europe

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an expanded indication for Merck & Co.’s PD-1 antagonist Keytruda (pembrolizumab).

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel